Trevi Therapeutics Q3 2026 Earnings Date & Estimates

Trevi Therapeutics (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company focused on developing treatments for chronic conditions that have limited therapeutic options. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine, an opioid receptor modulator designed to combine kappa-opioid receptor agonism with mu-opioid receptor antagonism.

Trevi is evaluating Haduvio in conditions involving chronic cough and severe itching. Its clinical development programs have included studies in chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, and chronic pruritus associated with systemic sclerosis, an autoimmune connective-tissue disorder. The company’s pipeline remains investigational, and its product candidates have not been established as safe and effective or approved for commercial use by regulatory authorities.

Founded in 2011 and headquartered in New Haven, Connecticut, Trevi conducts its research and clinical development activities through collaborations with investigators and clinical sites. The company became publicly traded on the Nasdaq under the symbol TRVI in 2019. Its operations are centered on advancing Haduvio through clinical testing and seeking potential regulatory approvals for patients with serious chronic conditions.